Artificial intelligence–based detection of treatment-emergent metastatic neuroendocrine carcinoma of prostate.
Abstract
36 Background: Metastatic prostate carcinoma is a highly heterogeneous disease with a wide morphological spectrum and disease outcomes. While some retain adenocarcinoma morphology, some undergo lineage plasticity and transform into treatment emergent neuroendocrine carcinoma (t-NEPC) with morphology similarity to small cell carcinoma and highly aggressive disease behavior. We developed a morphology-based artificial intelligence (AI) tool applicable in real-world metastatic biopsies to assist the diagnosis of t-NEPC on digital whole-slide images (WSIs). Methods: Using a previously presented deep-learning based supervised learning algorithm, which was trained with localized prostate specimens with NEPC morphology in whole slide images (WSIs) using a custom-designed UNet model, here we fine tuned this algorithm using 62 metastatic biopsies from our institution with WSIs of H&E sections (enriched for t-NEPC, n=15, 24%), bench marking with GU pathologist’s diagnosis (adenocarcinoma vs. poorly differentiated carcinoma vs. t-NEPC) to generate a continuous t-NEPC score (range 0-1, with 1 most likely represent t-NEPC) for each slide. The algorithm was further tested in a non-overlapping external cohort (West Coast Dream Team and PROMOTE cohorts) of 167 metastatic biopsies with H&E WSIs (including 7 t-NEPC, 4%). Results: In our institutional cohort for fine tuning (n=62), t-NEPC score was significantly higher in 15 cases with a pathology diagnosis of t-NEPC compared to those with adenocarcinoma or poorly differentiated carcinoma. Using t-NEPC score >0.05 as a cutoff, the concordance rate between the AI t-NEPC score and pathologists was 94% t-NEPC and 56% for adenocarcinoma. In the validation cohort (West Coast Dream Team and PROMOTE, n=167), the algorithm still separated t-NEPC from adenocarcinoma, but not significantly in poorly differentiated carcinoma, with a concordance rate 71% for t-NEPC 77% for adenocarcinoma. Conclusions: As a proof-of-principle study, a morphology-based AI t-NEPC score established from a localized NEPC classifier was applicable towards the diagnosis of t-NEPC with a high concordance rate with GU pathologists. Adenocarcinoma Poorly differentiated Carcinoma t-NEPC Institutional cohort (n=62) N, % 34, 55% 12, 19% 15, 24% t-NEPC score (mean, +/- STD) 0.14, 0.20 0.09, 0.15 0.38, 0.21 Concordance (n, %) 19/34, 56% N/A 14/15, 94% West Coast Dream Team and PROMOTE cohorts (n=162) N, % 100, 62% 60, 37% 7, 4% t-NEPC score (mean, +/- STD) 0.05, 0.12 0.08, 0.17 0.24, 0.33 Concordance (n, %) 77/100, 77% N/A 5/7, 71%
Article Details
Journal Info
Journal of Clinical Oncology
Lippincott Williams & Wilkins
Authors (15)
Chien-Kuang Cornelia Ding
Carolina Gomes-Alexandre
Johns Hopkins University, Baltimore, MD
Lia De Paula Oliveira
Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD
Sanaz Nourmohammadi Abadchi
Brendan Raizenne
University of California, San Francisco, San Francisco, CA
Eric Erak
Brigham and Women's Hospital, Boston, MA
Nilanjan Chattopadhyay
AIRA Matrix, Thane, India
Uttara Joshi
AIRA Matrix, Thane, India
Chaith Kondragunta
AIRA Matrix, Thane, India
Nitin Singhal
AIRA Matrix, Thane, India
David Quigley
Department of Physics, University of Warwick 2 , Gibbet Hill Road, Coventry CV4 7AL,
Jiaoti Huang
From the Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda (A.B.A., N.S., S.N., L.L., L.C.), the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore (J.H.-C.), and the Investigational Drug Branch, Cancer Therapy Evaluation Program, National Cancer Institute, National Institutes of Health, Rockville (H.S., E.S.) — all in Maryland; the Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN (K.V.B., M.O., C.M., G.P.B.); AdventHealth Cancer Institute and the University of Central Florida, Orlando (G.S.); Dana–Farber/Harvard Cancer Center, Boston (S.B., B.M.); UNC Lineberger Comprehensive Cancer Center, Chapel Hill (W.Y.K.), and Duke University Medical Center and Duke Cancer Institute, Durham (J.H., S.H.) — both in North Carolina; the University of Kansas Cancer Center, Westwood (R.P.); Memorial Sloan Kettering Cancer Center, New York (M.Y.T., M.J.M., J.E.R.), and Roswell Park Comprehensive Cancer Center, Buffalo (G.C.) — both in...
Eric J. Small
Angelo M. De Marzo
Johns Hopkins University Department of Biophysics, Baltimore, MD
Tamara L. Lotan